PISCATAWAY, NJ: Earlier this week, INNOPHARMA LLC announced that the United States Food and Drug Administration (FDA) has approved an Abbreviated New Drug Application (ANDA) submitted for its levetiracetam injection, which is the generic version of the Keppra® injection by UCB Inc.
INNOPHARMA go into a licensed agreement with X-GEN Pharmaceuticals, Inc for marketing and distribution of the generic version of the Keppra® injection in the US.
With particular focus on production of niche generic drugs and specialty pharmaceutical products, INNOPHARMA is a sterile product development company that has a widespread infrastructure for the development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities via a business model of internal product development and commercialization licensure. Globally, INNOPHARMA works with manufacturing and clinical research organizations for the commercialization of its developed products. Visit www.innopharmallc.comfor more information about INNOPHARMA.
X-GEN Pharmaceuticals, Inc. lays emphasis on the production, manufacture, and delivery of specialty pharmaceutical products that provide efficient, generic versions of drugs to the healthcare community. X-GEN’s broad range of product line presents a wide spectrum of dosage forms including injectables, anti-infective solutions, oral solids, and inhalants. Call (866) 390-4411, or visit the web-site at www.x-gen.us for more information about X-GEN Pharmaceuticals, Inc.